Cover Image
Read Now

Rituximab for the treatment of myasthenia gravis a review of clinical effectiveness, cost-effectiveness, and guidelines

The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updat...

Full description

Bibliographic Details
Main Authors: Banerjee, Srabani, Adcock, Lorna (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH August 14, 2018, 2018
Edition:Version 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Canada
Receptor Protein-tyrosine Kinases / Drug Effects
Cost-benefit Analysis
Treatment Outcome
Myasthenia Gravis / Drug Therapy
Rituximab / Therapeutic Use
Rituximab / Economics
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The purpose of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis (MG). Additionally, this report aims to review the evidence-based guidelines regarding the use of rituximab for the treatment of MG. This report updates a previous CADTH report and in addition has a broader scope
Physical Description:1 PDF file (41 pages) illustrations

Similar Items